At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.
Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026.
Hanmi will receive $75m upfront and may earn up to $1.185bn in milestone payments for development and approvals.
The approval relies on positive data from the POTOMAC Phase III trial.
Innovent Biologics will receive $650m upfront and could earn up to $9.85bn in additional milestone payments.
As the first psychedelics near approval, several other factors warrant attention to ensure effective and safe implementation.
